Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Researchers complete examination of class of type 2 medication.
Read More »Study Explores Mechanisms Behind Cardiovascular Benefits of SGLT2 inhibitors
What You Need to Know About SGLT2i Use in Obesity
Therapy offers beneficial weight loss in treatment of diabetes, but which agent in the class leads to the greatest body weight reduction?
Read More »Jim McDermott Current Interview
Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.
Read More »Jim McDermott Full Interview
In this Exclusive Interview, Dr. Jim McDermott talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about AstraZeneca SGLT-2 research, including the CVD-REAL large outcomes trial.
Read More »Jim McDermott Part 1, AstraZeneca SGLT2 Trials
In part 1 of this Exclusive Interview, Dr. Jim McDermott explains the recent AstraZeneca SGLT2 trials in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »Jim McDermott Part 2, Efficacy Of SGLT2 Inhibitors
In part 2 of this Exclusive Interview, Dr. Jim McDermott explains what research shows about the the efficacy of SGLT2 inhibitors and their benefit to risk ratio in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »Jim McDermott Part 3, Results From The Duration-8 Study
In part 3 of this Exclusive Interview, Dr. Jim McDermott explains the DURATION-8 study of Bydureon and dapagliflozin combo therapy in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »Jim McDermott Part 4, SGLT2 Effects On Patients
In part 4 of this Exclusive Interview, Dr. Jim McDermott discusses patient response to the DURATION-8 study, and the continuation of the study in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »Jim McDermott Part 5, AstraZeneca DapaCare
In part 5 of this Exclusive Interview, Dr. Jim McDermott explains DapaCare, the umbrella term that covers AstraZeneca's clinical program with Farxiga (dapagliflozin) in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »Jim McDermott Part 6, SGLT2 Cardiovascular Trials
In part 6, the conclusion of this Exclusive Interview, Dr. Jim McDermott explains SGLT2 cardiovascular trials, including the DECLARE trial that will complete in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »